Bloomfield M S, Butler W C
Pharmaceutical Development Sciences, GlaxoWellcome, Temple Hill, Dartford, DA1 5AH, Kent, UK.
Int J Pharm. 2000 Sep 25;206(1-2):55-61. doi: 10.1016/s0378-5173(00)00509-3.
The use of experimental design for the robustness testing of a flow-through dissolution method (Ph Eur/USP Apparatus 4) for atovaquone, one of the drug substances in a dual-active anti-malarial tablet formulation, Malarone tablets, is described. This procedure was developed to overcome the suppression of the atovaquone solubility, caused by the presence of the co-drug proguanil hydrochloride and potential imprecision due to the poor solubility of the coating material in the basic dissolution media employed. For this testing a quarter fractional two-level factorial design was applied, assessing six factors in sixteen experiments, with a further six centre points to assess natural experimental variation. Results demonstrate that the method is robust to small changes in all the main factors evaluated at sample times of 30 min or greater. At 15 min, variations in the concentration of sodium hydroxide in the dissolution media, peristaltic pump speed and flow rate were assessed as statistically significant. This observation is a result of the initial steepness of the dissolution release curve and hence these factors are now controlled routinely in the method. Release of this poorly soluble drug is limited at the 45 min time point (Q=75%) according to pharmacopoeial guidelines. The approach may be applied for other dissolution procedures.
描述了使用实验设计对一种流通溶解方法(欧洲药典/美国药典装置4)进行稳健性测试,该方法用于检测双活性抗疟片剂配方(玛拉隆片剂)中的一种原料药阿托伐醌。开发此程序是为了克服由于存在共同药物盐酸氯胍而导致的阿托伐醌溶解度抑制,以及由于包衣材料在所使用的碱性溶解介质中溶解度差而可能产生的不精确性。对于此测试,应用了四分之一分数二级析因设计,在16次实验中评估6个因素,还有另外6个中心点用于评估自然实验变异。结果表明,在30分钟或更长的取样时间下,该方法对所有评估的主要因素的微小变化具有稳健性。在15分钟时,溶解介质中氢氧化钠浓度、蠕动泵速度和流速的变化在统计学上被评估为显著。这一观察结果是溶解释放曲线初始陡峭度的结果,因此这些因素现在在该方法中被常规控制。根据药典指南,这种难溶性药物在45分钟时间点的释放有限(Q = 75%)。该方法可应用于其他溶解程序。